公开(公告)号：US20110257153A1

公开(公告)日：2011-10-20

申请号：US13091498

申请日：2011-04-21

Applicant: Genesis M. Bacani ,  Scott D. Bembenek ,  Wendy Eccles ,  James P. Edwards ,  Matthew T. Epperson ,  Laurent Gomez ,  Cheryl A. Grice ,  Aaron M. Kearney ,  Adrienne M. Landry-Bayle ,  Alice Lee-Dutra ,  Kelly J. Mcclure ,  Taraneh Mirzadegan ,  Alexandro Santillan, JR.

Inventor： Genesis M. Bacani ,  Scott D. Bembenek ,  Wendy Eccles ,  James P. Edwards ,  Matthew T. Epperson ,  Laurent Gomez ,  Cheryl A. Grice ,  Aaron M. Kearney ,  Adrienne M. Landry-Bayle ,  Alice Lee-Dutra ,  Kelly J. Mcclure ,  Taraneh Mirzadegan ,  Alexandro Santillan, JR.

IPC: A61K31/428 ,  C12N9/99 ,  C07D451/02 ,  A61K31/46 ,  A61K31/4995 ,  C07D487/04 ,  C07D471/04 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/5377 ,  A61P29/00 ,  A61P17/00 ,  A61P11/06 ,  A61P1/00 ,  A61P9/10 ,  A61P17/02 ,  C07D487/08

CPC classification number: C07D487/08 ,  C07D417/12 ,  C07D451/04 ,  C07D471/04 ,  C07D471/08 ,  C07D487/04

Abstract: Aryl-substituted bridged or fused diamine compounds, pharmaceutical compositions containing them, and methods of using the compounds and the pharmaceutical compositions for leukotriene A4 hydrolase (LTA4H or LTA4H) modulation and for the treatment of disease states, disorders, and conditions mediated by LTA4H activity, such as allergy, asthma, autoimmune diseases, pruritis, inflammatory bowel disease, ulcerative colitis, and cardiovascular disease, including atherosclerosis and prevention of myocardial infarction.